Loading
Governments and philanthropists commit large payments for whoever achieves a verified jump in ten-year cure rates for a specific cancer, however they do it.
Drug incentives reward incremental progression-free survival in late-stage disease; nothing rewards curing. Prize and advance market commitment mechanisms have worked for vaccines and longitude. The proposal is a set of cure prizes, each defined as a verified increase in a specific cancer's five- or ten-year relapse-free survival in a defined population (for example, pancreatic adenocarcinoma stage II, glioblastoma, metastatic triple-negative breast cancer), funded by pooled public and philanthropic commitments, awarded on registry-verified population outcomes with pro-rata payments for partial progress and open licensing conditions.
Shares Incentives reward me-too drugs and marginal gains, Glioma & glioblastoma, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
Shares Funding follows fashion, not burden, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma.
Shares Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden.
Shares Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/